|
Q2 FY2024
As of Jun 30, 2025
|
Q1 FY2024
As of Mar 31, 2025
|
Q4 FY2023
As of Dec 31, 2024
|
Q3 FY2023
As of Sep 30, 2024
|
Q2 FY2023
As of Jun 30, 2024
|
Q1 FY2023
As of Mar 31, 2024
|
Q4 FY2022
As of Dec 31, 2023
|
Q3 FY2022
As of Sep 30, 2023
|
Q2 FY2022
As of Jun 30, 2023
|
Q1 FY2022
As of Mar 31, 2023
|
Q4 FY2021
As of Dec 31, 2022
|
Q3 FY2021
As of Sep 30, 2022
|
Q2 FY2021
As of Jun 30, 2022
|
Q1 FY2021
As of Mar 31, 2022
|
Q4 FY2020
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||
| Current Assets: | |||||||||||||||
| Cash | |||||||||||||||
| Prepaid expenses | |||||||||||||||
| Total Current Assets | |||||||||||||||
| Other assets | |||||||||||||||
| Cash and Investments held in the Trust Account | |||||||||||||||
| Total Assets | |||||||||||||||
| LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT | |||||||||||||||
| Current Liabilities: | |||||||||||||||
| Accounts payable and accrued expenses | |||||||||||||||
| Advances from related parties | |||||||||||||||
| Accrued offering costs | |||||||||||||||
| Convertible promissory notes - related parties | |||||||||||||||
| Total Current Liabilities | |||||||||||||||
| Derivative liabilities | |||||||||||||||
| Deferred underwriting commission | |||||||||||||||
| Total Liabilities | |||||||||||||||
| Class A ordinary shares subject to possible redemption; 2,640,370 and 7,129,558 shares (at redemption value of $12.00 and $11.68 per share as of June 30, 2025 and December 31, 2024, respectively) | |||||||||||||||
| Shareholders’ deficit: | |||||||||||||||
| Ordinary shares, value, issued | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Accumulated deficit | |||||||||||||||
| Total Shareholders’ Deficit | |||||||||||||||
| Total Liabilities, Ordinary Shares subject to Possible Redemption and Shareholders’ Deficit | |||||||||||||||
Loading...
